BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 36707670)

  • 1. TOR1B: a predictor of bone metastasis in breast cancer patients.
    Nguyen MN; Akter S; Akhter H; Ansary S; Han S; Shin Y; Ha J; Kang I; Kim SS; Choi TG
    Sci Rep; 2023 Jan; 13(1):1495. PubMed ID: 36707670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER+ breast cancer.
    Alfarsi LH; Elansari R; Toss MS; Diez-Rodriguez M; Nolan CC; Ellis IO; Rakha EA; Green AR
    Breast Cancer Res Treat; 2019 Jan; 173(1):93-102. PubMed ID: 30306428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel secretome-to-transcriptome integrated or secreto-transcriptomic approach to reveal liquid biopsy biomarkers for predicting individualized prognosis of breast cancer patients.
    Ankney JA; Xie L; Wrobel JA; Wang L; Chen X
    BMC Med Genomics; 2019 May; 12(1):78. PubMed ID: 31146747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors, prognostic factors, and nomograms for bone metastasis in patients with newly diagnosed infiltrating duct carcinoma of the breast: a population-based study.
    Huang Z; Hu C; Liu K; Yuan L; Li Y; Zhao C; Hu C
    BMC Cancer; 2020 Nov; 20(1):1145. PubMed ID: 33238981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone marrow mammaglobin-1 (SCGB2A2) immunohistochemistry expression as a breast cancer specific marker for early detection of bone marrow micrometastases.
    Talaat IM; Hachim MY; Hachim IY; Ibrahim RAE; Ahmed MAER; Tayel HY
    Sci Rep; 2020 Aug; 10(1):13061. PubMed ID: 32747636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a Novel Prognostic Signature Based on Antigen Processing and Presentation in Patients with Breast Cancer.
    Qi A; Ju M; Liu Y; Bi J; Wei Q; He M; Wei M; Zhao L
    Pathol Oncol Res; 2021; 27():600727. PubMed ID: 34257557
    [No Abstract]   [Full Text] [Related]  

  • 7. The prognostic role of RANK SNP rs34945627 in breast cancer patients with bone metastases.
    Ferreira A; Alho I; Vendrell I; Melo M; Brás R; Costa AL; Sousa AR; Mansinho A; Abreu C; Pulido C; Macedo D; Pacheco T; Correia L; Costa L; Casimiro S
    Oncotarget; 2016 Jul; 7(27):41380-41389. PubMed ID: 27191503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic significance of STAT3 in invasive breast cancer: analysis of protein and mRNA expressions in large cohorts.
    Aleskandarany MA; Agarwal D; Negm OH; Ball G; Elmouna A; Ashankyty I; Nuglozeh E; Fazaludeen MF; Diez-Rodriguez M; Nolan CC; Tighe PJ; Green AR; Ellis IO; Rakha EA
    Breast Cancer Res Treat; 2016 Feb; 156(1):9-20. PubMed ID: 26907764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trefoil factor 1 (TFF1) is a potential prognostic biomarker with functional significance in breast cancers.
    Yi J; Ren L; Li D; Wu J; Li W; Du G; Wang J
    Biomed Pharmacother; 2020 Apr; 124():109827. PubMed ID: 31986408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors associated with bone metastasis in breast cancer: a systematic review and meta-analysis.
    Liu H; Zhang X; Zhang S; Wang X; Yu S
    Ann Palliat Med; 2021 Apr; 10(4):4435-4452. PubMed ID: 33966394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk, Prognostic Factors and Nomograms for Bone Metastasis in Young Females with Breast Cancer: A Large Cohort Retrospective Study.
    Liu Z; Xue J; Liu K; Fan Z; Liu D; Wang D
    Altern Ther Health Med; 2023 Jan; 29(1):182-190. PubMed ID: 36074969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer.
    Aljohani AI; Joseph C; Kurozumi S; Mohammed OJ; Miligy IM; Green AR; Rakha EA
    Breast Cancer Res Treat; 2020 Jun; 181(3):541-551. PubMed ID: 32350677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High IRF8 expression correlates with CD8 T cell infiltration and is a predictive biomarker of therapy response in ER-negative breast cancer.
    Gatti G; Betts C; Rocha D; Nicola M; Grupe V; Ditada C; Nuñez NG; Roselli E; Araya P; Dutto J; Boffelli L; Fernández E; Coussens LM; Maccioni M
    Breast Cancer Res; 2021 Mar; 23(1):40. PubMed ID: 33766090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer.
    Darlix A; Griguolo G; Thezenas S; Kantelhardt E; Thomssen C; Dieci MV; Miglietta F; Conte P; Braccini AL; Ferrero JM; Bailleux C; Jacot W; Guarneri V
    J Neurooncol; 2018 Jun; 138(2):369-382. PubMed ID: 29488184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological Characteristics and Breast Cancer-Specific Survival of Patients With Single Hormone Receptor-Positive Breast Cancer.
    Li Y; Yang D; Yin X; Zhang X; Huang J; Wu Y; Wang M; Yi Z; Li H; Li H; Ren G
    JAMA Netw Open; 2020 Jan; 3(1):e1918160. PubMed ID: 31899528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen receptor 1 and progesterone receptor are distinct biomarkers and prognostic factors in estrogen receptor-positive breast cancer: Evidence from a bioinformatic analysis.
    Wu JR; Zhao Y; Zhou XP; Qin X
    Biomed Pharmacother; 2020 Jan; 121():109647. PubMed ID: 31733575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disseminated Tumor Cells in the Bone Marrow of Patients with Operable Primary Breast Cancer: Prognostic Impact in Immunophenotypic Subgroups and Clinical Implication for Bisphosphonate Treatment.
    Stefanovic S; Diel I; Sinn P; Englert S; Hennigs A; Mayer C; Schott S; Wallwiener M; Blumenstein M; Golatta M; Heil J; Rom J; Sohn C; Schneeweiss A; Schuetz F; Domschke C
    Ann Surg Oncol; 2016 Mar; 23(3):757-66. PubMed ID: 26467455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast cancer patients with brain metastases or leptomeningeal disease: 10-year results of a national cohort with validation of prognostic indexes.
    Znidaric T; Gugic J; Marinko T; Gojkovic Horvat A; Paulin Kosir MS; Golo D; Ivanetic Pantar M; Ratosa I
    Breast J; 2019 Nov; 25(6):1117-1125. PubMed ID: 31286623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Receptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence-free survival and development of bone metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657).
    Vidula N; Yau C; Li J; Esserman LJ; Rugo HS
    Breast Cancer Res Treat; 2017 Aug; 165(1):129-138. PubMed ID: 28577080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of novel biomarkers associated with poor patient outcomes in invasive breast carcinoma.
    Canevari RA; Marchi FA; Domingues MA; de Andrade VP; Caldeira JR; Verjovski-Almeida S; Rogatto SR; Reis EM
    Tumour Biol; 2016 Oct; 37(10):13855-13870. PubMed ID: 27485113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.